Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,520 across all filing types
Latest filing 2024-03-25 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - SEMAGLUTIDE INJECTION FOR OVERWEIGHT/OBESITY INDICATION OBTAINS CLINICAL TRIAL APPROVAL
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the clinical trial approval of a product (Semaglutide Injection) by the National Medical Products Administration of China. It contains no financial data, no detailed financial performance, no regulatory certifications, and no mention of shareholder votes or management changes. The document is relatively short (3267 characters) and serves as a public announcement of a clinical trial approval, which is a regulatory or corporate update rather than a financial report or detailed management discussion. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a report publication announcement since it is not announcing the release of a report but rather a clinical trial approval. The best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory or corporate announcements that do not fit other categories.
2024-03-25 English
VOLUNTARY ANNOUNCEMENT - DAPAGLIFLOZIN TABLETS OBTAINS DRUG REGISTRATION APPROVAL
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the drug registration approval of a product (Dapagliflozin Tablets). It is a short announcement (2075 characters) and does not contain financial data, financial results, or detailed report content. It is not an annual report, earnings release, or any detailed financial or management report. It is also not a regulatory filing in the sense of officer certifications or compliance documents. The announcement is about a product approval, which is a corporate update but does not fit into categories like M&A, capital update, or legal proceedings. Given the nature and length, and that it is a voluntary announcement about a product approval, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other categories.
2024-03-22 English
VOLUNTARY ANNOUNCEMENT - ANTIBODY-DRUG CONJUGATE SYS6023 OBTAINS CLINICAL TRIAL APPROVAL
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the clinical trial approval of a new antibody-drug conjugate product. It is a short announcement (2079 characters) and does not contain financial data, detailed management discussion, or regulatory filings related to financial performance. It is not an annual or interim report, earnings release, or any form of detailed financial or governance report. The content focuses on a clinical trial approval, which is a corporate update but not related to capital/financing, board changes, or legal proceedings. Given the nature and length, it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2024-03-20 English
CASH DIVIDEND ANNOUNCEMENT FOR EQUITY ISSUER
Notice of Dividend Amount Classification · 100% confidence The document is titled 'Final Dividend for the year ended 31 December 2023' and contains detailed information about the dividend amount, payment dates, ex-dividend date, record date, and other dividend-related logistics. It does not contain financial statements or broader financial performance data. The document length is 3853 characters, which is relatively short and focused solely on dividend information. Therefore, this document is an announcement of dividend amount and payment details, fitting the category of 'Notice of Dividend Amount' (DIV).
2024-03-20 English
ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
Annual Report Classification · 95% confidence The document is an announcement of the audited consolidated annual results for the year ended 31 December 2023 by CSPC Pharmaceutical Group Limited. It includes detailed financial highlights, chairman's statement, management discussion and analysis, business review, and outlook. The content covers comprehensive financial performance, business operations, and future plans, typical of an Annual Report. The document length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or summary. Therefore, it fits the definition of an Annual Report (10-K). FY 2023
2024-03-20 English
VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE MAT2A INHIBITOR (SYH2039)OBTAINS CLINICAL TRIAL APPROVAL
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the clinical trial approval of a new drug (SYH2039). It is not a financial report, earnings release, or regulatory filing related to financial performance or governance changes. The document is short (2632 characters) and serves as an announcement of a significant event (clinical trial approval) rather than a detailed report or presentation. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is also not related to capital changes, mergers, or legal proceedings. Given the nature and content, this is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2024-03-18 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.